Wockhardt loss narrows to Rs 86 crore in Q3
New Delhi: Pharmaceuticals firm Wockhardt Ltd has reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023.
Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said.
Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.
Read also: Wockhardt Gets CDSCO Panel Nod To study combination of cefepime and zidebactam
Headquartered in Mumbai, Wockhardt is an Indian pharmaceutical and biotechnology company. The Company produces biopharmaceuticals, nutrition products, formulations, vaccines and active pharmaceutical ingredients (APIs). Its manufacturing plants are located in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.
Original news source: https://www.ptinews.com/story/business/wockhardt-q3-loss-narrows-to-rs-86-cr/1290002
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.